UPDATE 3-BioMarin says data shows hemophilia gene therapy effects could wane
May 28, 2019 at 18:02 PM EDT
BioMarin Pharmaceutical Inc said on Tuesday early trial data for its gene therapy for hemophilia A suggested the one-time infusion's effect on some patients' bleeding disorders would last eight years.